The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
07-May-18
$7.1 billion
Target:
Frutarom
Acquiror:
International Flavors and Fragrances
Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition
28-Jul-22
Pending
$1.6 billion
Target:
Derco Holdings
Acquiror:
Inchcape Plc
Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America
29-Sep-21
~$1.1 billion
Target:
Procaps Group
Acquiror:
Union Acquisition Corp. II (NASDAQ: LATN)
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
22-Dec-16
$290 million
Target:
Subsidiaries and affiliates of Empresas Indumotora S.A.
Acquiror:
Inchcape PLC
Advised Inchcape PLC, a global leader in automotive retail and distribution, on the acquisition of a multi-country scale distribution business in Chile, Peru, Colombia, and Argentina for $290m (approximately £234m)
26-Mar-18
$284 million
Target:
Grupo Rudelman
Acquiror:
Inchcape PLC
Advised Inchcape PLC, a global leader in automotive and distribution, on the acquisition of Grupo Rudelman, a Suzuki-focused distribution business in Costa Rica and Panama
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
10-Aug-11
$65 million
Target:
Grupo Aeromexico S.A. de C.V
Acquiror:
Delta Air Lines, Inc.
Advised Delta Air Lines, Inc. in connection with its strategic minority investment in Grupo Aeromexico S.A. de C.V
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
03-Mar-10
$NA
Target:
Puerta Mexico Transportation Facility
Acquiror:
Kansas City Southern
Advised Ports America, Inc., a portfolio company of Highstar Capital, on its sale of Puerta Mexico, a state-of-the-art customs-clearing intermodal transportation facility located in the Mexico City market
23-Dec-19
$NA
Target:
Infracommerce
Acquiror:
Group of undisclosed Brazilian investors
Advised Brazil-based Infracommerce, a leader in designing, building and delivering the digital B2C and B2B go-to-market strategy for large enterprises, on its Series E funding round
16-Jan-20
$NA
Target:
Daimler's Mercedes-Benz passenger car and private vans distribution operations in Colombia
Acquiror:
Inchcape PLC
Advised Inchcape, a leading global independent multi-brand automotive distributor, on its acquisition of the Mercedes-Benz passenger car and private vans distribution operations in Colombia from Daimler Colombia
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
22-Dec-15
$NA
Target:
Hortifruti
Acquiror:
Partners Group
Advised Hortifruti, Brazil's number one premium retailer of healthy food, on the sale of a significant minority stake to Partners Group, a global private markets investment manager
28-Feb-20
$NA
Target:
Rights to Three Skin Care Brands in Mexico
Acquiror:
Grisi Hnos
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the Mexico rights to Hinds, Capent and Eclipsol to Mexico-based Grisi Hnos
23-Nov-16
$NA
Target:
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Acquiror:
Arrow Generiques SAS
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
29-Jul-20
$NA
Target:
Integrated supplier of preserved and frozen vegetables
Acquiror:
ACON Agri Investments S.L.
Advised ACON Agri Investments S.L., a special purpose vehicle of ACON Investments LLC, on the acquisition of Grupo Alsur, a leading integrated supplier of preserved and frozen vegetables with operations in Spain and Peru
01-Aug-17
$NA
Target:
Deltaplam
Acquiror:
Sealed Air Corporation
Advised Deltaplam, a Brazilian flexible packaging manufacturer, on its 100% sale to Sealed Air Corporation, a global provider of knowledge-based food, product and medical packaging solutions
02-Oct-17
$NA
Target:
Mãe Terra Produtos Naturais Ltda.
Acquiror:
The Unilever Group
Advised Mãe Terra Produtos Naturais Ltda., Brazil’s leading Natural & Organic food products company, on its sale to The Unilever Group
07-Dec-21
Pending
Undisclosed
Target:
Interamericana Trading Corporation and Simpson Motors
Acquiror:
Inchcape plc
Advising Inchcape plc, the leading independent global automotive distributor, on the acquisition of Interamericana Trading Corporation (“ITC”), a leading independent automotive distributor in the Caribbean region, and Simpson Motors, the leading automotive retailer in Barbados, from the Simpson Group
19-Jan-16
$NA
Target:
Recepta Biopharma
Acquiror:
Inova Empresa Fundo de Investimento em Participações
Advised Recepta Biopharma on a capital raise